Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Prostate Cancer

  Free Subscription


Articles published in Prostate

Retrieve available abstracts of 269 articles:
HTML format



Single Articles


    December 2022
  1. AMARO GM, da Silva ADT, Tamarindo GH, Lamas CA, et al
    Differential effects of omega-3 PUFAS on tumor progression at early and advanced stages in TRAMP mice.
    Prostate. 2022;82:1491-1504.
    PubMed     Abstract available


  2. DENMEADE S, Lim SJ, Isaaccson Velho P, Wang H, et al
    PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.
    Prostate. 2022;82:1529-1536.
    PubMed     Abstract available


    November 2022
  3. NAITO Y, Kato M, Kawanishi H, Yamamoto A, et al
    Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
    Prostate. 2022 Nov 24. doi: 10.1002/pros.24462.
    PubMed     Abstract available


  4. SU CT, Nizialek E, Berchuck JE, Vlachostergios PJ, et al
    Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancer.
    Prostate. 2022 Nov 16. doi: 10.1002/pros.24454.
    PubMed     Abstract available


  5. ALASKAR A, Abdulraqeb Ali A, Hassan S, Shinwari Z, et al
    Inhibition of signaling downstream of beta-2 adrenoceptor by propranolol in prostate cancer cells.
    Prostate. 2022 Nov 14. doi: 10.1002/pros.24455.
    PubMed     Abstract available


  6. TRABZONLU L, Pienta KJ, Trock BJ, De Marzo AM, et al
    Presence of cells in the polyaneuploid cancer cell (PACC) state predicts the risk of recurrence in prostate cancer.
    Prostate. 2022 Nov 13. doi: 10.1002/pros.24459.
    PubMed     Abstract available


  7. PANUNZIO A, Sorce G, Hoeh B, Hohenhorst L, et al
    Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5.
    Prostate. 2022 Nov 6. doi: 10.1002/pros.24458.
    PubMed     Abstract available


  8. CHAN JSK, Tang P, Hui JMH, Lee YHA, et al
    Association between duration of gonadotrophin-releasing hormone agonist use and cardiovascular risks: A population-based competing-risk analysis.
    Prostate. 2022;82:1477-1480.
    PubMed     Abstract available


  9. BROWN NE, Jones A, Hunt BG, Waltz SE, et al
    Prostate tumor RON receptor signaling mediates macrophage recruitment to drive androgen deprivation therapy resistance through Gas6-mediated Axl and RON signaling.
    Prostate. 2022;82:1422-1437.
    PubMed     Abstract available


    October 2022
  10. LEE EE, Singh T, Hu C, Han M, et al
    The impact of salvage radiotherapy initiation at PSA
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24452.
    PubMed     Abstract available


  11. OISHI T, Hatakeyama S, Tabata R, Fujimori D, et al
    Effects of apalutamide dose reduction on skin-related adverse events in patients with advanced prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Oct 31. doi: 10.1002/pros.24453.
    PubMed     Abstract available


  12. NIU S, Liu Y, Ding X, Xu Y, et al
    (18) F-DCFPyL positron emission tomography/magnetic resonance imaging-guided ultrasound fusion biopsy is an identical pathway in prostate cancer diagnosis.
    Prostate. 2022 Oct 25. doi: 10.1002/pros.24446.
    PubMed     Abstract available


  13. ODERDA M, Albisinni S, Benamran D, Calleris G, et al
    Accuracy of elastic fusion biopsy: Comparing prostate cancer detection between targeted and systematic biopsy.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24449.
    PubMed     Abstract available


  14. SATAPATHY S, Das CK, Aggarwal P, Sood A, et al
    Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    Prostate. 2022 Oct 19. doi: 10.1002/pros.24450.
    PubMed     Abstract available


  15. CHENG S, Yu X
    CTPC, a combined transcriptome data set of human prostate cancer cell lines.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24448.
    PubMed     Abstract available


  16. HARPER JB, Greenberg SE, Hunt TC, Cooney KA, et al
    Initial outcomes and insights from a novel high-risk prostate cancer screening clinic.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24447.
    PubMed     Abstract available


  17. OU W, Lei J, Li M, Zhang X, et al
    Ultrasound-based radiomics score for pre-biopsy prediction of prostate cancer to reduce unnecessary biopsies.
    Prostate. 2022 Oct 7. doi: 10.1002/pros.24442.
    PubMed     Abstract available


  18. HARTRAMPF PE, Weinzierl FX, Seitz AK, Kubler H, et al
    Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
    Prostate. 2022;82:1406-1412.
    PubMed     Abstract available


  19. VERMA S, Kushwaha PP, Shankar E, Ponsky LE, et al
    Increased cytokine gene expression and cognition risk associated with androgen deprivation therapy.
    Prostate. 2022;82:1389-1399.
    PubMed     Abstract available


  20. WONG WW, Hillman DW, Daniels TB, Vargas CE, et al
    A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of life.
    Prostate. 2022;82:1338-1345.
    PubMed     Abstract available


    September 2022
  21. LEE YHA, Hui JMH, Chan JSK, Liu K, et al
    Metformin use and mortality in Asian, diabetic patients with prostate cancer on androgen deprivation therapy: A population-based study.
    Prostate. 2022 Sep 30. doi: 10.1002/pros.24443.
    PubMed     Abstract available


  22. MUSTAFFA A, Emara S
    Safely omitting bone isotope scans in a cohort of grade group 2 prostate cancer.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24444.
    PubMed     Abstract available


  23. URABE F, Miki K, Kimura T, Sasaki H, et al
    Long-term outcomes of radical prostatectomy versus low-dose-rate brachytherapy in patients with intermediate-risk prostate cancer: Propensity score matched comparison.
    Prostate. 2022 Sep 29. doi: 10.1002/pros.24445.
    PubMed     Abstract available


  24. WANG S, Zhang C, Xu Z, Chen MH, et al
    Differential impact of PI3K/AKT/mTOR signaling on tumor initiation and progression in animal models of prostate cancer.
    Prostate. 2022 Sep 26. doi: 10.1002/pros.24441.
    PubMed     Abstract available


  25. ALAMIRI J, Britton CJ, Ahmed ME, Andrews JR, et al
    Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis.
    Prostate. 2022 Sep 11. doi: 10.1002/pros.24413.
    PubMed     Abstract available


  26. SCHMID FA, Lieger L, Saba K, Sigg S, et al
    Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24435.
    PubMed     Abstract available


  27. LIN R, Yang Y, Wu E, Zhou M, et al
    SIRT2 promotes cell proliferation and migration through mediating ERK1/2 activation and lactosylceramide accumulation in prostate cancer.
    Prostate. 2022 Sep 8. doi: 10.1002/pros.24437.
    PubMed     Abstract available


  28. SCHOBER JP, Stensland KD, Moinzadeh A, Canes D, et al
    Holmium laser enucleation of the prostate in men on active surveillance for prostate cancer with refractory lower urinary tract symptoms secondary to enlarged prostates.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24433.
    PubMed     Abstract available


  29. KC M, Oral E, Rung AL, Trapido E, et al
    Prostate cancer aggressiveness and financial toxicity among prostate cancer patients.
    Prostate. 2022 Sep 5. doi: 10.1002/pros.24434.
    PubMed     Abstract available


    August 2022
  30. SEMIZ HS, Kucuk U, Kisa E, Keskinkilic M, et al
    CD47 (don't eat me signal) expression levels and its relationship with clinicopathologic features in early-stage prostate carcinoma.
    Prostate. 2022 Aug 28. doi: 10.1002/pros.24432.
    PubMed     Abstract available


  31. RUAN X, Huang D, Huang J, Xu D, et al
    Application of European-specific polygenic risk scores for predicting prostate cancer risk in different ancestry populations.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24431.
    PubMed     Abstract available


  32. KARELIA DN, Kim S, Plano D, Sharma AK, et al
    Seleno-aspirin compound AS-10 promotes histone acetylation ahead of suppressing androgen receptor transcription, G1 arrest, and apoptosis of prostate cancer cells.
    Prostate. 2022 Aug 22. doi: 10.1002/pros.24430.
    PubMed     Abstract available


  33. DYMANUS K, Howard LE, Oyekunle T, De Hoedt AM, et al
    Are higher pre-diagnosis follicle stimulating hormone levels associated with long-term prostate cancer risk?
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24429.
    PubMed     Abstract available


  34. FILON MJ, Gillette AA, Yang B, Khemees TA, et al
    Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
    Prostate. 2022 Aug 18. doi: 10.1002/pros.24428.
    PubMed     Abstract available


  35. MAYNARD JP, Godwin TN, Lu J, Vidal I, et al
    Localization of macrophage subtypes and neutrophils in the prostate tumor microenvironment and their association with prostate cancer racial disparities.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24424.
    PubMed     Abstract available


  36. TAKAMORI H, Urabe F, Matsuzaki J, Kimura S, et al
    Circulating microRNA profiling for prediction of oncological outcomes in prostate cancer patients following radical prostatectomy.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24427.
    PubMed     Abstract available


  37. TERRACCIANO D, La Civita E, Athanasiou A, Liotti A, et al
    New strategy for the identification of prostate cancer: The combination of Proclarix and the prostate health index.
    Prostate. 2022 Aug 16. doi: 10.1002/pros.24422.
    PubMed     Abstract available


  38. WANG S, Ryan Russell J, Drescher M, Park A, et al
    Prostate cancer grade downgrading at time of prostatectomy provides risk-stratification insight into future tumor behavior after prostatectomy.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24425.
    PubMed     Abstract available


  39. LOMBARDO R, Rovesti L, Cicione A, Gravina C, et al
    Serum levels of chromogranin are not predictive of poorly differentiated prostate cancer: Results from a multicenter radical prostatectomy cohort.
    Prostate. 2022 Aug 3. doi: 10.1002/pros.24412.
    PubMed     Abstract available


  40. KWAN EM, Wyatt AW
    Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer.
    Prostate. 2022;82 Suppl 1:S25-S36.
    PubMed     Abstract available


  41. SUTERA P, Deek MP, Van der Eecken K, Wyatt AW, et al
    Genomic biomarkers to guide precision radiotherapy in prostate cancer.
    Prostate. 2022;82 Suppl 1:S73-S85.
    PubMed     Abstract available


  42. KHAN HM, Cheng HH
    Germline genetics of prostate cancer.
    Prostate. 2022;82 Suppl 1:S3-S12.
    PubMed     Abstract available


  43. CRESTA MORGADO P, Mateo J
    Clinical implications of homologous recombination repair mutations in prostate cancer.
    Prostate. 2022;82 Suppl 1:S45-S59.
    PubMed     Abstract available


  44. COTTER K, Rubin MA
    The evolving landscape of prostate cancer somatic mutations.
    Prostate. 2022;82 Suppl 1:S13-S24.
    PubMed     Abstract available


  45. ANTONARAKIS ES
    Genetics and genomics of prostate cancer and therapeutic implications.
    Prostate. 2022;82 Suppl 1:S1-S2.
    PubMed    


  46. MIZUNO K, Beltran H
    Future directions for precision oncology in prostate cancer.
    Prostate. 2022;82 Suppl 1:S86-S96.
    PubMed     Abstract available


  47. CHOUDHURY AD
    PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.
    Prostate. 2022;82 Suppl 1:S60-S72.
    PubMed     Abstract available


  48. LI G, Xia YF, Huang YX, Okat D, et al
    Better preservation of erectile function in localized prostate cancer patients with modern proton therapy: Is it cost-effective?
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24417.
    PubMed     Abstract available


  49. UCAR T, Gunduz N, Demirci E, Culpan M, et al
    Comparison of 68Ga-PSMA PET/CT and mp-MRI in regard to local staging for prostate cancer with histopathological results: A retrospective study.
    Prostate. 2022 Aug 1. doi: 10.1002/pros.24420.
    PubMed     Abstract available


    July 2022
  50. YAZGAN SC, Yekeduz E, Utkan G, Urun Y, et al
    Prognostic role of pan-immune-inflammation value in patients with metastatic castration-resistant prostate cancer treated with androgen receptor-signaling inhibitors.
    Prostate. 2022 Jul 28. doi: 10.1002/pros.24419.
    PubMed     Abstract available


  51. KHAN S, Vohra S, Farnan L, Elmore SNC, et al
    Using health insurance claims data to assess long-term disease progression in a prostate cancer cohort.
    Prostate. 2022 Jul 26. doi: 10.1002/pros.24418.
    PubMed     Abstract available


  52. WANG Y, Tang Y, Gao X, Gan Y, et al
    Optimization of prostate cancer patient lymph node staging via the integration of neutrophil-lymphocyte ratios, platelet-lymphocyte ratios, and (68) Ga-PSMA-PET-derived SUVmax values.
    Prostate. 2022 Jul 21. doi: 10.1002/pros.24415.
    PubMed     Abstract available


  53. MIYAHIRA AK, Soule HR
    The 28th Annual Prostate Cancer Foundation Scientific Retreat report.
    Prostate. 2022 Jul 18. doi: 10.1002/pros.24409.
    PubMed     Abstract available


  54. MODONUTTI D, Majdalany SE, Corsi N, Li P, et al
    A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24403.
    PubMed     Abstract available


  55. RAMIREZ-TORRES A, Reagan AL, Howard LE, Wiggins E, et al
    Racial differences in circulating mitochondria-derived peptides may contribute to prostate cancer health disparities.
    Prostate. 2022 Jul 5. doi: 10.1002/pros.24398.
    PubMed     Abstract available


    June 2022
  56. YANAGISAWA T, Kimura T, Hata K, Narita S, et al
    Does castration status affect docetaxel-related adverse events? :Identification of risk factors for docetaxel-related adverse events in metastatic prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24406.
    PubMed     Abstract available


  57. CASADO-LLOMBART S, Ajami T, Consuegra-Fernandez M, Carreras E, et al
    Gene variation impact on prostate cancer progression: Lymphocyte modulator, activation, and cell adhesion gene variant contribution.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24407.
    PubMed     Abstract available


  58. BRAY AW, Duan R, Malalur P, Drusbosky LM, et al
    Elevated serum CEA is associated with liver metastasis and distinctive circulating tumor DNA alterations in patients with castration-resistant prostate cancer.
    Prostate. 2022 Jun 29. doi: 10.1002/pros.24400.
    PubMed     Abstract available


  59. MIURA Y, Hatakeyama S, Narita S, Kimura T, et al
    Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24404.
    PubMed     Abstract available


  60. YANG T, Liu Y, Chen S, Tian J, et al
    Serum prolactin level as a predictive factor for abiraterone response in patients with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24402.
    PubMed     Abstract available


  61. HEARD JR, Huang AJ, Werle L, Adler K, et al
    Definitive treatment choice among Black immigrants with prostate cancer: Analysis of patient surveys distributed at a single safety-net institution.
    Prostate. 2022 Jun 23. doi: 10.1002/pros.24399.
    PubMed     Abstract available


  62. STENZL A, Szmulewitz RZ, Petrylak D, Holzbeierlein J, et al
    The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
    Prostate. 2022 Jun 8. doi: 10.1002/pros.24396.
    PubMed     Abstract available


  63. LIU AJ, Kosiorek HE, Ueberroth BE, Jaeger E, et al
    The impact of genetic aberrations on response to radium-223 treatment for castration-resistant prostate cancer with bone metastases.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24375.
    PubMed     Abstract available


  64. SORCE G, Hoeh B, Flammia RS, Chierigo F, et al
    Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24376.
    PubMed     Abstract available


  65. CHO HL, Murthy V, Mouw KW, D'Amico AV, et al
    Second malignancy probabilities in patients with prostate cancer treated with whole pelvis radiation therapy versus prostate only radiation therapy.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24362.
    PubMed     Abstract available


  66. ABDI B, Basset N, Perrot E, Benderra MA, et al
    DNA damage repair gene germline profiling for metastatic prostate cancer patients of different ancestries.
    Prostate. 2022 Jun 2. doi: 10.1002/pros.24374.
    PubMed     Abstract available


  67. MUNOZ-MORENO L, Carmena MJ, Prieto JC, Schally AV, et al
    Tumorigenic transformation of human prostatic epithelial cell line RWPE-1 by growth hormone-releasing hormone (GHRH).
    Prostate. 2022;82:933-941.
    PubMed     Abstract available


  68. FUJIWARA M, Numao N, Yamamoto S, Ishikawa Y, et al
    Predictive ability of prebiopsy magnetic resonance imaging and biopsy for side-specific negative lymph node metastasis at radical prostatectomy.
    Prostate. 2022;82:904-910.
    PubMed     Abstract available


  69. HOLZE S, Lemaire E, Mende M, Neuhaus P, et al
    Quality of life after robotic-assisted and laparoscopic radical prostatectomy: Results of a multicenter randomized controlled trial (LAP-01).
    Prostate. 2022;82:894-903.
    PubMed     Abstract available


  70. RATNANI P, Dovey Z, Parekh S, Sobotka S, et al
    Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
    Prostate. 2022;82:970-983.
    PubMed     Abstract available


    May 2022
  71. ASKER H, Yilmaz-Oral D, Oztekin CV, Gur S, et al
    An update on the current status and future prospects of erectile dysfunction following radical prostatectomy.
    Prostate. 2022 May 17. doi: 10.1002/pros.24366.
    PubMed     Abstract available


  72. PELLEGRINO F, Stabile A, Mazzone E, Sorce G, et al
    Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series.
    Prostate. 2022 May 10. doi: 10.1002/pros.24368.
    PubMed     Abstract available


  73. HE Y, Shen Q, Fu W, Wang H, et al
    Optimized grade group for reporting prostate cancer grade in systematic and MRI-targeted biopsies.
    Prostate. 2022 May 10. doi: 10.1002/pros.24365.
    PubMed     Abstract available


  74. MORGANS AK, Chen YH, Jarrard DF, Carducci M, et al
    Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
    Prostate. 2022 May 10. doi: 10.1002/pros.24369.
    PubMed     Abstract available


  75. SAKELLAKIS M
    Orphan receptors in prostate cancer.
    Prostate. 2022 May 10. doi: 10.1002/pros.24370.
    PubMed     Abstract available


  76. KEEGAN NM, Vasselman SE, Barnett ES, Nweji B, et al
    Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality.
    Prostate. 2022 May 10. doi: 10.1002/pros.24363.
    PubMed     Abstract available


  77. DENMEADE S, Antonarakis ES, Markowski MC
    Bipolar androgen therapy (BAT): A patient's guide.
    Prostate. 2022;82:753-762.
    PubMed     Abstract available


  78. VITEK RA, Huang W, Geiger PG, Heninger E, et al
    Fresh tissue procurement and preparation for multicompartment and multimodal analysis of the prostate tumor microenvironment.
    Prostate. 2022;82:836-849.
    PubMed     Abstract available


  79. LUNACEK A, Tischler M, Mrstik C, Hebenstreit D, et al
    Effects of cycling and rowing on serum concentrations of prostate-specific antigen: A randomized study of 101 male subjects.
    Prostate. 2022;82:804-808.
    PubMed     Abstract available


    April 2022
  80. BOSLAND MC, Horton L, Condon MS
    Effects of green tea on prostate carcinogenesis in rat models and a human prostate cancer xenograft model.
    Prostate. 2022 Apr 29. doi: 10.1002/pros.24364.
    PubMed     Abstract available


  81. WITHROW D, Pilleron S, Nikita N, Ferlay J, et al
    Current and projected number of years of life lost due to prostate cancer: A global study.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24360.
    PubMed     Abstract available


  82. WANG M, Qi J, George AK, Semerjian A, et al
    The added influence of genomics and post-MRI confirmatory biopsy results to MRI results alone on medical decision making for men with favorable risk prostate cancer being considered for active surveillance.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24357.
    PubMed     Abstract available


  83. HU Q, Hong X, Xu L, Jia R, et al
    A nomogram for accurately predicting the pathological upgrading of prostate cancer, based on (68) Ga-PSMA PET/CT.
    Prostate. 2022 Apr 25. doi: 10.1002/pros.24358.
    PubMed     Abstract available


  84. YUEN KC, Tran B, Anton A, Hamidi H, et al
    Molecular classification of hormone-sensitive and castration-resistant prostate cancer, using nonnegative matrix factorization molecular subtyping of primary and metastatic specimens.
    Prostate. 2022 Apr 18. doi: 10.1002/pros.24346.
    PubMed     Abstract available


  85. PITAK-ARNNOP P, Messer-Peti R, Tangmanee C, Neff A, et al
    Prostate cancer awareness among transgender women after gender-affirming surgery.
    Prostate. 2022 Apr 13. doi: 10.1002/pros.24355.
    PubMed     Abstract available


  86. MORI JO, Shafran JS, Stojanova M, Katz MH, et al
    Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24351.
    PubMed     Abstract available


  87. FLAMMIA RS, Hoeh B, Sorce G, Chierigo F, et al
    Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24350.
    PubMed     Abstract available


  88. LV X, Li Y, Li R, Guan X, et al
    Relationships of sleep traits with prostate cancer risk: A prospective study of 213,999 UK Biobank participants.
    Prostate. 2022 Apr 11. doi: 10.1002/pros.24345.
    PubMed     Abstract available


  89. SORCE G, Flammia RS, Hoeh B, Chierigo F, et al
    Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24349.
    PubMed     Abstract available


  90. YAMAGUCHI M, Murata T, Ramos JW
    Overexpression of regucalcin blocks the migration, invasion, and bone metastatic activity of human prostate cancer cells: Crosstalk between cancer cells and bone cells.
    Prostate. 2022 Apr 1. doi: 10.1002/pros.24348.
    PubMed     Abstract available


  91. ZHOU Z, Liang Z, Zuo Y, Zhou Y, et al
    Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
    Prostate. 2022;82:556-565.
    PubMed     Abstract available


  92. CHEN Z, Wu J, Sun K, He Y, et al
    Risk model based on MRI fusion biopsy characteristics predicts biochemical recurrence after radical prostatectomy.
    Prostate. 2022;82:566-575.
    PubMed     Abstract available


  93. LINDH C, Samaratunga H, Delahunt B, Bergstrom R, et al
    Ductal and acinar components of mixed prostatic adenocarcinoma frequently have a common clonal origin.
    Prostate. 2022;82:576-583.
    PubMed     Abstract available


  94. WEI X, Roudier MP, Kwon OJ, Lee JD, et al
    Paracrine Wnt signaling is necessary for prostate epithelial proliferation.
    Prostate. 2022;82:517-530.
    PubMed     Abstract available


    March 2022
  95. GRAHAM LS, Schweizer MT
    Mismatch repair deficiency and clinical implications in prostate cancer.
    Prostate. 2022 Mar 31. doi: 10.1002/pros.24343.
    PubMed     Abstract available


  96. PREISSER F, Heinze A, S Abrams-Pompe R, Budaus L, et al
    Impact of positive surgical margin length and Gleason grade at the margin on oncologic outcomes in patients with nonorgan-confined prostate cancer.
    Prostate. 2022 Mar 28. doi: 10.1002/pros.24341.
    PubMed     Abstract available


  97. SINGH CK, Denu RA, Nihal M, Shabbir M, et al
    PLK4 is upregulated in prostate cancer and its inhibition reduces centrosome amplification and causes senescence.
    Prostate. 2022 Mar 25. doi: 10.1002/pros.24342.
    PubMed     Abstract available


  98. MAO F, Kong Y, Liu J, Rao X, et al
    Diptoindonesin G antagonizes AR signaling and enhances the efficacy of antiandrogen therapy in prostate cancer.
    Prostate. 2022 Mar 24. doi: 10.1002/pros.24336.
    PubMed     Abstract available


  99. LUNDGREN PO, Tribukait B, Kjellman A, Norming U, et al
    Serum thymidine kinase 1 concentration as a predictive biomarker in prostate cancer.
    Prostate. 2022 Mar 16. doi: 10.1002/pros.24335.
    PubMed     Abstract available


  100. SADAGHIANI MS, Sheikhbahaei S, Werner RA, Pienta KJ, et al
    (177) Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: An updated systematic review and meta-analysis.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24325.
    PubMed     Abstract available


  101. ZHANG T, Kephart J, Bronson E, Anand M, et al
    Prospective clinical trial of disulfiram plus copper in men with metastatic castration-resistant prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24329.
    PubMed     Abstract available


  102. ANTONARAKIS ES, Tierno M, Fisher V, Tukachinsky H, et al
    Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.
    Prostate. 2022 Mar 14. doi: 10.1002/pros.24331.
    PubMed     Abstract available


  103. SENTANA-LLEDO D, Sartor O, Balk SP, Einstein DJ, et al
    Immune mechanisms behind prostate cancer in men of African ancestry: A review.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24333.
    PubMed     Abstract available


  104. BECKMANN KR, Bangma CH, Helleman J, Bjartell A, et al
    Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database.
    Prostate. 2022 Mar 7. doi: 10.1002/pros.24330.
    PubMed     Abstract available


  105. HINOJOSA-GONZALEZ DE, Roblesgil-Medrano A, Torres-Martinez M, Alanis-Garza C, et al
    Single-port versus multiport robotic-assisted radical prostatectomy: A systematic review and meta-analysis on the da Vinci SP platform.
    Prostate. 2022;82:405-414.
    PubMed     Abstract available


  106. LEITSMANN C, Uhlig A, Bremmer F, Mut TT, et al
    Impact of mpMRI targeted biopsy on intraoperative nerve-sparing (NeuroSAFE) during robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:493-501.
    PubMed     Abstract available


  107. KOPARAL MY, Sozen TS, Karsiyakali N, Aslan G, et al
    Comparison of transperineal and transrectal targeted prostate biopsy using Mahalanobis distance matching within propensity score caliper method: A multicenter study of Turkish Urooncology Association.
    Prostate. 2022;82:425-432.
    PubMed     Abstract available


    February 2022
  108. CHIERIGO F, Borghesi M, Wurnschimmel C, Flammia RS, et al
    Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24317.
    PubMed     Abstract available


  109. PURAYIL HT, Daaka Y
    betaArrestin1 regulates glucocorticoid receptor mitogenic signaling in castration-resistant prostate cancer.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24324.
    PubMed     Abstract available


  110. LIU JM, Chen YT, Wu CT, Hsu WL, et al
    Androgen deprivation therapy for prostate cancer and the risk of thyroid diseases.
    Prostate. 2022 Feb 28. doi: 10.1002/pros.24323.
    PubMed     Abstract available


  111. K C M, Oral E, Rung AL, Trapido EJ, et al
    Neighborhood deprivation and risk of mortality among men with prostate cancer: Findings from a long-term follow-up study.
    Prostate. 2022 Feb 24. doi: 10.1002/pros.24320.
    PubMed     Abstract available


  112. KANEKO M, Fukuda N, Nagano H, Yamada K, et al
    Artificial intelligence trained with integration of multiparametric MR-US imaging data and fusion biopsy trajectory-proven pathology data for 3D prediction of prostate cancer: A proof-of-concept study.
    Prostate. 2022 Feb 22. doi: 10.1002/pros.24321.
    PubMed     Abstract available


  113. IZOL V, Ok F, Aslan G, Akdogan B, et al
    Effect of pelvic lymph node dissection and its extent on oncological outcomes in intermediate-risk prostate cancer patients: A multicenter study of the Turkish Uro-oncology Association.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24318.
    PubMed     Abstract available


  114. OZBEK B, Ertunc O, Erickson A, Vidal ID, et al
    Multiplex immunohistochemical phenotyping of T cells in primary prostate cancer.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24315.
    PubMed     Abstract available


  115. HOEH B, Flammia RS, Hohenhorst L, Sorce G, et al
    Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24313.
    PubMed     Abstract available


  116. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups.
    Prostate. 2022 Feb 21. doi: 10.1002/pros.24312.
    PubMed     Abstract available


  117. PAGEL CN, Kularathna PK, Sanaei R, Young ND, et al
    Protease-activated receptor-2 dependent and independent responses of bone cells to prostate cancer cell secretory products.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24316.
    PubMed     Abstract available


  118. WANG Y, Abenojar EC, Wang J, de Leon AC, et al
    Development of a novel castration-resistant orthotopic prostate cancer model in New Zealand White rabbit.
    Prostate. 2022 Feb 15. doi: 10.1002/pros.24314.
    PubMed     Abstract available


  119. STAMIS SA, Heath EI, Lucas S, Boerner J, et al
    Alcohol dehydrogenase expression patterns in normal prostate, benign prostatic hyperplasia, and prostatic adenocarcinoma in African American and Caucasian men.
    Prostate. 2022 Feb 8. doi: 10.1002/pros.24310.
    PubMed     Abstract available


  120. SUN Y, Ai JZ, Jin X, Liu LR, et al
    IL-8 protects prostate cancer cells from GSK-3beta-induced oxidative stress by activating the mTOR signaling pathway.
    Prostate. 2022;82:401-402.
    PubMed    


  121. URAKAMI A, Arimura H, Takayama Y, Kinoshita F, et al
    Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.
    Prostate. 2022;82:330-344.
    PubMed     Abstract available


  122. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Response to the letter to the editor: "Don't throw the baby out with the bath water" by Horsley et al.
    Prostate. 2022;82:399-400.
    PubMed    


  123. HORSLEY PJ, Kneebone A, Eade TN, Hruby G, et al
    Don't throw the baby out with the bath water.
    Prostate. 2022;82:397-398.
    PubMed    


  124. MA C, Downes M, Jain R, Ientilucci M, et al
    Prevalence of adverse pathology features in grade group 2 prostatectomy specimens with syn- or metachronous metastatic disease.
    Prostate. 2022;82:345-351.
    PubMed     Abstract available


  125. ZENNER ML, Helou YB, Deaton RJ, Sverdlov M, et al
    Advanced glycation end-products (AGEs) are lower in prostate tumor tissue and inversely related to proportion of West African ancestry.
    Prostate. 2022;82:306-313.
    PubMed     Abstract available


  126. ARCOT R, Cher ML, Qi J, Linsell SM, et al
    Delayed radical prostatectomy after a period of active surveillance is not associated with the use of secondary treatments compared with immediate prostatectomy.
    Prostate. 2022;82:323-329.
    PubMed     Abstract available


  127. TAN YG, Fang AHS, Lim JKS, Khalid F, et al
    Incorporating artificial intelligence in urology: Supervised machine learning algorithms demonstrate comparative advantage over nomograms in predicting biochemical recurrence after prostatectomy.
    Prostate. 2022;82:298-305.
    PubMed     Abstract available


  128. MA H, Xu W, Ni J, Zhao N, et al
    Phase I clinical trial of HC-1119 soft capsule in Chinese healthy adult male subjects: Pharmacokinetics and safety of single-dose proportionality and effects of food.
    Prostate. 2022;82:276-285.
    PubMed     Abstract available


  129. LI N, Song WJ, Gao J, Xu ZP, et al
    The prognostic nutritional index predicts the biochemical recurrence of patients treated with robot-assisted laparoscopic radical prostatectomy.
    Prostate. 2022;82:221-226.
    PubMed     Abstract available


  130. AUSSAVAVIROJEKUL P, Hoonlor A, Srinualnad S
    Optimization of clinical risk-factor interpretation and radiological findings with machine learning for PIRADS category 3 patients.
    Prostate. 2022;82:235-244.
    PubMed     Abstract available


  131. SIEDOW M, Eisner M, Yaney A, Washington I, et al
    Impact of prostate biopsy secondary pathology review on radiotherapy management.
    Prostate. 2022;82:210-215.
    PubMed     Abstract available


    January 2022
  132. LUNA VELEZ MV, Paulino da Silva Filho O, Verhaegh GW, van Hooij O, et al
    Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24309.
    PubMed     Abstract available


  133. GARCIA-MARQUES F, Liu S, Totten SM, Bermudez A, et al
    Protein signatures to distinguish aggressive from indolent prostate cancer.
    Prostate. 2022 Jan 31. doi: 10.1002/pros.24307.
    PubMed     Abstract available


  134. ZHAO R, Lv Y, Feng T, Zhang R, et al
    ATF6alpha promotes prostate cancer progression by enhancing PLA2G4A-mediated arachidonic acid metabolism and protecting tumor cells against ferroptosis.
    Prostate. 2022 Jan 28. doi: 10.1002/pros.24308.
    PubMed     Abstract available


  135. STOVER EH, Oh C, Keskula P, Choudhury AD, et al
    Implementation of a prostate cancer-specific targeted sequencing panel for credentialing of patient-derived cell lines and genomic characterization of patient samples.
    Prostate. 2022 Jan 27. doi: 10.1002/pros.24305.
    PubMed     Abstract available


  136. MOLL JM, Hofland J, Teubel WJ, de Ridder CMA, et al
    Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24297.
    PubMed     Abstract available


  137. ZHU S, Zhang Z, Zhang H, Liu Z, et al
    DNA-repair status should be assessed in treatment-emergent neuroendocrine prostate cancer before platinum-based therapy.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24292.
    PubMed     Abstract available


  138. ZHOU J, Chen H, Wu Y, Shi B, et al
    Plasma IL-6 and TNF-alpha levels correlate significantly with grading changes in localized prostate cancer.
    Prostate. 2022 Jan 17. doi: 10.1002/pros.24299.
    PubMed     Abstract available


  139. CAO Y, Song DY, Deville C, DeWeese TL, et al
    Radiating the prostate bed in relapsed oligometastatic prostate cancer: How comprehensive should we be?
    Prostate. 2022 Jan 11. doi: 10.1002/pros.24301.
    PubMed     Abstract available


  140. RASPIN K, O'Malley DE, Marthick JR, Donovan S, et al
    Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Prostate. 2022 Jan 7. doi: 10.1002/pros.24300.
    PubMed     Abstract available


  141. VLACHOSTERGIOS PJ, Niaz MJ, Thomas C, Christos PJ, et al
    Pilot study of the diagnostic utility of (89) Zr-df-IAB2M and (68) Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer.
    Prostate. 2022 Jan 5. doi: 10.1002/pros.24294.
    PubMed     Abstract available


  142. SEREF C, Acar O, Kilic M, Vural M, et al
    Histologically benign PI-RADS 4 and 5 lesions contain cancer-associated epigenetic alterations.
    Prostate. 2022;82:145-153.
    PubMed     Abstract available


  143. YUAN W, Liu B, Sanda M, Wei R, et al
    Glycoforms of human prostate-specific membrane antigen (PSMA) in human cells and prostate tissue.
    Prostate. 2022;82:132-144.
    PubMed     Abstract available


  144. WIDJAJA L, Derlin T, Ross TL, Bengel FM, et al
    Pretherapeutic estimated glomerular filtration rate predicts development of chronic kidney disease in patients receiving PSMA-targeted radioligand therapy.
    Prostate. 2022;82:86-96.
    PubMed     Abstract available


    December 2021
  145. SNIPAITIENE K, Bakavicius A, Lazutka JR, Ulys A, et al
    Urinary microRNAs can predict response to abiraterone acetate in castration resistant prostate cancer: A pilot study.
    Prostate. 2021 Dec 30. doi: 10.1002/pros.24293.
    PubMed     Abstract available


  146. MIKOSHI A, Miyai K, Hamabe F, Edo H, et al
    MRI-detectability and histological factors of prostate cancer including intraductal carcinoma and cribriform pattern.
    Prostate. 2021 Dec 28. doi: 10.1002/pros.24291.
    PubMed     Abstract available


  147. SIENKIEWICZ K, Yang C, Paschal BM, Ratan A, et al
    Genomic analyses of the metastasis-derived prostate cancer cell lines LNCaP, VCaP, and PC3-AR.
    Prostate. 2021 Dec 24:e24290. doi: 10.1002/pros.24290.
    PubMed     Abstract available


  148. HE H, Han D, Xu F, Lyu J, et al
    How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis.
    Prostate. 2021 Dec 20. doi: 10.1002/pros.24287.
    PubMed     Abstract available


  149. URABE F, Miki K, Kimura T, Sasaki H, et al
    Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24289.
    PubMed     Abstract available


  150. KAUFMANN B, Saba K, Schmidli TS, Stutz S, et al
    Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Prostate. 2021 Dec 16. doi: 10.1002/pros.24286.
    PubMed     Abstract available


  151. BARLOW SK, Oyekunle T, Janes JL, De Hoedt AM, et al
    Prostate weight and prostate cancer outcomes after radical prostatectomy: Results from the SEARCH cohort study.
    Prostate. 2021 Dec 14. doi: 10.1002/pros.24283.
    PubMed     Abstract available


  152. LEFEBVRE F, Blanchet-Deverly A, Michineau L, Blanchet P, et al
    Metabolic syndrome and prostate cancer in Afro-Caribbean men.
    Prostate. 2021 Dec 14:e24281. doi: 10.1002/pros.24281.
    PubMed     Abstract available


  153. POCKROS B, Stensland KD, Parries M, Frankenberger E, et al
    Preoperative MRI PI-RADS scores are associated with prostate cancer upstaging on surgical pathology.
    Prostate. 2021 Dec 8. doi: 10.1002/pros.24280.
    PubMed     Abstract available


  154. ZAREI A, Javid H, Sanjarian S, Senemar S, et al
    Metagenomics studies for the diagnosis and treatment of prostate cancer.
    Prostate. 2021 Dec 2. doi: 10.1002/pros.24276.
    PubMed     Abstract available


  155. MATTI B, Reeves F, Prouse M, Zargar-Shoshtari K, et al
    The impact of the extent and location of positive surgical margins on the risk of biochemical recurrence following radical prostatectomy in men with Gleason 7 prostate cancers.
    Prostate. 2021;81:1428-1434.
    PubMed     Abstract available


  156. NAYAN M, Salari K, Bozzo A, Ganglberger W, et al
    Predicting survival after radical prostatectomy: Variation of machine learning performance by race.
    Prostate. 2021;81:1355-1364.
    PubMed     Abstract available


  157. YAMOAH K, Asamoah FA, Abrahams AOD, Awasthi S, et al
    Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study.
    Prostate. 2021;81:1402-1410.
    PubMed     Abstract available


  158. TAKEZAWA K, Fujita K, Matsushita M, Motooka D, et al
    The Firmicutes/Bacteroidetes ratio of the human gut microbiota is associated with prostate enlargement.
    Prostate. 2021;81:1287-1293.
    PubMed     Abstract available


  159. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant.
    Prostate. 2021;81:1294-1302.
    PubMed     Abstract available


    November 2021
  160. NAKAYAMA H, Sekine Y, Oka D, Miyazawa Y, et al
    Combination therapy with novel androgen receptor antagonists and statin for castration-resistant prostate cancer.
    Prostate. 2021 Nov 29. doi: 10.1002/pros.24274.
    PubMed     Abstract available


  161. VESTRIS PG, Gourtaud G, Senechal C, Sadreux Y, et al
    Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Prostate. 2021 Nov 25. doi: 10.1002/pros.24270.
    PubMed     Abstract available


  162. PLAMBECK BD, Wang LL, Mcgirr S, Jiang J, et al
    Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24261.
    PubMed     Abstract available


  163. PREISSER F, Wurnschimmel C, Pose RM, Heinze A, et al
    Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Prostate. 2021 Nov 22. doi: 10.1002/pros.24268.
    PubMed     Abstract available


  164. NAKAZAWA M, Fang M, H Marshall C, Lotan TL, et al
    Clinical and genomic features of SPOP-mutant prostate cancer.
    Prostate. 2021 Nov 15. doi: 10.1002/pros.24269.
    PubMed     Abstract available


  165. TRYGGESTAD AMA, Axcrona K, Axcrona U, Bigalke I, et al
    Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy.
    Prostate. 2021 Nov 11. doi: 10.1002/pros.24267.
    PubMed     Abstract available


  166. HANSKE J, Risse Y, Roghmann F, Pucheril D, et al
    Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24264.
    PubMed     Abstract available


  167. MIYAHIRA AK, Zarif JC, Coombs CC, Flavell RR, et al
    Prostate cancer research in the 21st century; report from the 2021 Coffey-Holden prostate cancer academy meeting.
    Prostate. 2021 Nov 3. doi: 10.1002/pros.24262.
    PubMed     Abstract available


    October 2021
  168. SHI Z, Lu L, Resurreccion WK, Yang W, et al
    Association of germline rare pathogenic mutations in guideline-recommended genes with prostate cancer progression: A meta-analysis.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24252.
    PubMed     Abstract available


  169. PILLING A, Kim SH, Hwang C
    Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Prostate. 2021 Oct 21. doi: 10.1002/pros.24257.
    PubMed     Abstract available


  170. LUO LS, Jiang JF, Luan HH, Zi H, et al
    Spatial and temporal patterns of prostate cancer burden and their association with Socio-Demographic Index in Asia, 1990-2019.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24258.
    PubMed     Abstract available


  171. KIM S, Li L, Zhang J, Jiang C, et al
    Aqueous metabolome of tissue-specific conditional Pten-knockout mouse prostate cancer and TRAMP neuroendocrine carcinoma.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24256.
    PubMed     Abstract available


  172. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Prostate. 2021 Oct 18. doi: 10.1002/pros.24253.
    PubMed     Abstract available


  173. WENZEL M, Colla Ruvolo C, Wurnschimmel C, Nocera L, et al
    Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24249.
    PubMed     Abstract available


  174. IKEUCHI W, Wakita Y, Zhang G, Li C, et al
    AT-rich interaction domain 5A regulates the transcription of interleukin-6 gene in prostate cancer cells.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24251.
    PubMed     Abstract available


  175. JIMBO M, Andrews JR, Ahmed ME, Dundar A, et al
    Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy.
    Prostate. 2021 Oct 11. doi: 10.1002/pros.24246.
    PubMed     Abstract available


  176. PREBAY ZJ, Medairos R, Doolittle J, Langenstroer P, et al
    The prognostic value of digital rectal exam for the existence of advanced pathologic features after prostatectomy.
    Prostate. 2021;81:1064-1070.
    PubMed     Abstract available


    September 2021
  177. YIN Y, Liu Q, Shao Y, He X, et al
    Regulatory mechanism of androgen receptor on NCAPD3 gene expression in prostate cancer.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24245.
    PubMed     Abstract available


  178. YU C, Niu L, Li L, Li T, et al
    Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
    Prostate. 2021 Sep 30. doi: 10.1002/pros.24229.
    PubMed     Abstract available


  179. YANAGISAWA T, Kimura T, Mori K, Suzuki H, et al
    Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
    Prostate. 2021 Sep 24. doi: 10.1002/pros.24243.
    PubMed     Abstract available


  180. YONEYAMA T, Yamamoto H, Sutoh Yoneyama M, Tobisawa Y, et al
    Characteristics of alpha2,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level.
    Prostate. 2021 Sep 21. doi: 10.1002/pros.24239.
    PubMed     Abstract available


  181. HERNANDEZ-LLODRA S, Segales L, Juanpere N, Marta Lorenzo T, et al
    SPOP and CHD1 alterations in prostate cancer: Relationship with PTEN loss, tumor grade, perineural infiltration, and PSA recurrence.
    Prostate. 2021 Sep 17. doi: 10.1002/pros.24218.
    PubMed     Abstract available


  182. HOEH B, Wurnschimmel C, Flammia RS, Horlemann B, et al
    Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients.
    Prostate. 2021 Sep 15. doi: 10.1002/pros.24235.
    PubMed     Abstract available


  183. JIMENEZ-ALCAIDE E, Garcia-Fuentes C, Hernandez V, De la Pena E, et al
    Influence of androgen deprivation therapy on the severity of COVID-19 in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24232.
    PubMed     Abstract available


  184. LETHONGSAVARN V, Pinault M, Diedhiou A, Guimaraes C, et al
    Tissue cholesterol metabolism and prostate cancer aggressiveness: Ethno-geographic variations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24234.
    PubMed     Abstract available


  185. AYDOS U, Cetin S, Akdemir UO, Budak FC, et al
    The role of histopathological and biochemical parameters for predicting metastatic disease on (68) Ga-PSMA-11 PET in prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24231.
    PubMed     Abstract available


  186. WATANABE R, Maekawa M, Kiyoi T, Kurata M, et al
    PSMA-positive membranes secreted from prostate cancer cells have potency to transform vascular endothelial cells into an angiogenic state.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24237.
    PubMed     Abstract available


  187. LIU Y, Dong Y, Liu J, Zhang X, et al
    Comparison between (18) F-DCFPyL PET and MRI for the detection of transition zone prostate cancer.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24230.
    PubMed     Abstract available


  188. CHHATRE S, Malkowicz SB, Jayadevappa R
    Continuity of care in acute survivorship phase, and short and long-term outcomes in prostate cancer patients.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24228.
    PubMed     Abstract available


  189. SOKOLOVA AO, Marshall CH, Lozano R, Gulati R, et al
    Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24236.
    PubMed     Abstract available


  190. CHO MC, Yoo S, Choo MS, Son H, et al
    Lymphocyte-to-monocyte ratio is a predictor of clinically significant prostate cancer at prostate biopsy.
    Prostate. 2021 Sep 13. doi: 10.1002/pros.24222.
    PubMed     Abstract available


  191. MANGOSH TL, Grabowska MM, Taylor DJ
    SLX4IP N-terminus dictates telomeric localization in ALT-like castration-resistant prostate cancer cell lines.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24225.
    PubMed     Abstract available


  192. MATSUDA T, Miyata Y, Nakamura Y, Otsubo A, et al
    Pathological significance and prognostic role of LATS2 in prostate cancer.
    Prostate. 2021 Sep 7. doi: 10.1002/pros.24226.
    PubMed     Abstract available


  193. MIYAHIRA AK, Soule HR
    The 27th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24211.
    PubMed     Abstract available


  194. SUMAN S, Parghane RV, Joshi A, Prabhash K, et al
    Combined (177) Lu-PSMA-617 PRLT and abiraterone acetate versus (177) Lu-PSMA-617 PRLT monotherapy in metastatic castration-resistant prostate cancer: An observational study comparing the response and durability.
    Prostate. 2021 Sep 1. doi: 10.1002/pros.24219.
    PubMed     Abstract available


  195. EKSI M, Evren I, Akkas F, Arikan Y, et al
    Machine learning algorithms can more efficiently predict biochemical recurrence after robot-assisted radical prostatectomy.
    Prostate. 2021;81:913-920.
    PubMed     Abstract available


  196. IAKYMENKO OA, Lugo I, Briski LM, Nemov I, et al
    Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Prostate. 2021;81:866-873.
    PubMed     Abstract available


  197. MARTINEZ O, Murphy C, Bsatee A, Abaza R, et al
    Impact of median lobe on urinary function after robotic prostatectomy.
    Prostate. 2021;81:832-837.
    PubMed     Abstract available


  198. LONERGAN PE, Cowan JE, Washington SL 3rd, Greenberg SA, et al
    Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort.
    Prostate. 2021;81:1009-1017.
    PubMed     Abstract available


  199. SANCHES BDA, Maldarine JS, Vilamaior PSL, Felisbino SL, et al
    Stromal cell interplay in prostate development, physiology, and pathological conditions.
    Prostate. 2021;81:926-937.
    PubMed     Abstract available


  200. WEE CE, Costello BA, Orme JJ, Quevedo JF, et al
    Chemotherapy with atezolizumab for small cell or neuroendocrine carcinoma of the prostate: A single institution experience.
    Prostate. 2021;81:938-943.
    PubMed     Abstract available


    August 2021
  201. LEDET EM, Sartor O
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24221.
    PubMed    


  202. DI MAIDA F, Grosso AA, Minervini A
    Letter to the Editor: "Family history and pathogenic/likely pathogenic germline variants in prostate cancer patients".
    Prostate. 2021 Aug 31. doi: 10.1002/pros.24220.
    PubMed    


  203. SHAO L, Wang J, Karatas O, Ittmann M, et al
    MEX3D is an oncogenic driver in prostate cancer.
    Prostate. 2021 Aug 29. doi: 10.1002/pros.24216.
    PubMed     Abstract available


  204. SUN BL
    Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24213.
    PubMed     Abstract available


  205. WANG Z, Zhu S, Zhao J, Nie L, et al
    The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
    Prostate. 2021 Aug 26. doi: 10.1002/pros.24215.
    PubMed     Abstract available


  206. OKINAKA Y, Kageyama S, Nishizawa K, Yoshida T, et al
    Clinical, pathological, and therapeutic features of newly diagnosed prostate cancer predominantly detected by opportunistic PSA screening: A survey of Shiga Prefecture, Japan.
    Prostate. 2021 Aug 21. doi: 10.1002/pros.24212.
    PubMed     Abstract available


  207. HAFFNER MC, Bhamidipati A, Tsai HK, Esopi DM, et al
    Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24210.
    PubMed     Abstract available


  208. WENZEL M, Wurnschimmel C, Nocera L, Ruvolo CC, et al
    The effect of primary urological cancers on survival in men with secondary prostate cancer.
    Prostate. 2021 Aug 16. doi: 10.1002/pros.24209.
    PubMed     Abstract available


  209. NANDALUR KR, Colvin R, Walker D, Nandalur SR, et al
    Benign prostate hyperplasia as a potential protective factor against prostate cancer: Insights from a magnetic resonance imaging study of compositional characteristics.
    Prostate. 2021 Aug 10. doi: 10.1002/pros.24207.
    PubMed     Abstract available


  210. WURNSCHIMMEL C, Wenzel M, Wang N, Tian Z, et al
    Long-term overall survival of radical prostatectomy patients is often superior to the general population: A comparison using life-table data.
    Prostate. 2021;81:785-793.
    PubMed     Abstract available


  211. WURNSCHIMMEL C, Wenzel M, Chierigo F, Flammia RS, et al
    Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns.
    Prostate. 2021;81:778-784.
    PubMed     Abstract available


  212. WAGASKAR VG, Ratnani P, Levy M, Moody K, et al
    Clinical characteristics and oncological outcomes in negative multiparametric MRI patients undergoing robot-assisted radical prostatectomy.
    Prostate. 2021;81:772-777.
    PubMed     Abstract available


    July 2021
  213. ROSSIGNOL T, Gourtaud G, Senechal C, Sadreux Y, et al
    Characteristics and progression-free survival of Afro-Caribbean men with metastatic hormone-sensitive prostate cancer at the time of diagnosis.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24206.
    PubMed     Abstract available


  214. LEIS-FILHO AF, Lainetti PD, Kobayashi PE, Palmieri C, et al
    Expression and prognostic significance of vascular endothelial growth factor-A (VEGF-A) and its receptor in canine prostate cancer.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24199.
    PubMed     Abstract available


  215. CAO Y, Zhang W, Li Y, Fu J, et al
    Rates and trends in stage-specific prostate cancer incidence by age and race/ethnicity, 2000-2017.
    Prostate. 2021 Jul 28. doi: 10.1002/pros.24204.
    PubMed     Abstract available


  216. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients.
    Prostate. 2021 Jul 26. doi: 10.1002/pros.24202.
    PubMed     Abstract available


  217. CHAO OS, Goodman OB Jr
    DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
    Prostate. 2021 Jul 23. doi: 10.1002/pros.24200.
    PubMed     Abstract available


  218. EPSTEIN JI
    Very low-risk versus low-risk prostate cancer: A distinction worth keeping.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24197.
    PubMed    


  219. WEI J, Yang W, Shi Z, Lu L, et al
    Observed evidence for guideline-recommended genes in predicting prostate cancer risk from a large population-based cohort.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24195.
    PubMed     Abstract available


  220. FETTKE H, Kwan EM, Bukczynska P, Steen JA, et al
    Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24194.
    PubMed     Abstract available


  221. LIU G, Zhu Y, Yao Z, Jiang Y, et al
    Development and validation of a predictive model for determining clinically significant prostate cancer in men with negative magnetic resonance imaging after transrectal ultrasound-guided prostate biopsy.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24193.
    PubMed     Abstract available


  222. HUANG D, Ruan X, Wu Y, Lin X, et al
    Genetic polymorphisms at 19q13.33 are associated with [-2]proPSA (p2PSA) levels and provide additional predictive value to prostate health index for prostate cancer.
    Prostate. 2021 Jul 12. doi: 10.1002/pros.24192.
    PubMed     Abstract available


  223. LAUNER BM, Lloyd GL
    Sociodemographic index and global trends in prostate cancer: 1990-2017.
    Prostate. 2021 Jul 5. doi: 10.1002/pros.24178.
    PubMed     Abstract available


  224. CHEN DY, Su PJ, See LC, Liu JR, et al
    Gonadotropin-releasing hormone antagonist associated with lower cardiovascular risk compared with gonadotropin-releasing hormone agonist in prostate cancer: A nationwide cohort and in vitro study.
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24187.
    PubMed     Abstract available


  225. BROGGI G, Lo Giudice A, Di Mauro M, Asmundo MG, et al
    SRSF-1 and microvessel density immunohistochemical analysis by semi-automated tissue microarray in prostate cancer patients with diabetes (DIAMOND study).
    Prostate. 2021 Jul 1. doi: 10.1002/pros.24185.
    PubMed     Abstract available


  226. CORRADI JP, Cumarasamy CW, Staff I, Tortora J, et al
    Identification of a five gene signature to predict time to biochemical recurrence after radical prostatectomy.
    Prostate. 2021;81:694-702.
    PubMed     Abstract available


    June 2021
  227. LV S, Pu X, Luo M, Wen H, et al
    Long noncoding RNA GAS5 interacts and suppresses androgen receptor activity in prostate cancer cells.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24186.
    PubMed     Abstract available


  228. WENZEL M, Wurnschimmel C, Ruvolo CC, Nocera L, et al
    Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24184.
    PubMed     Abstract available


  229. LENDINEZ-CANO G, Ojeda-Claro AV, Gomez-Gomez E, Morales Jimenez P, et al
    Prospective study of diagnostic accuracy in the detection of high-grade prostate cancer in biopsy-naive patients with clinical suspicion of prostate cancer who underwent the Select MDx test.
    Prostate. 2021 Jun 29. doi: 10.1002/pros.24182.
    PubMed     Abstract available


  230. BASU HS, Wilganowski N, Robertson S, Reuben JM, et al
    Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
    Prostate. 2021 Jun 25. doi: 10.1002/pros.24146.
    PubMed     Abstract available


  231. NUNES-XAVIER CE, Kildal W, Kleppe A, Danielsen HE, et al
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.
    PubMed     Abstract available


  232. WURNSCHIMMEL C, Kachanov M, Wenzel M, Mandel P, et al
    Twenty-year trends in prostate cancer stage and grade migration in a large contemporary german radical prostatectomy cohort.
    Prostate. 2021 Jun 10. doi: 10.1002/pros.24181.
    PubMed     Abstract available


  233. FALEGAN OS, Jarvi K, Vogel HJ, Hyndman ME, et al
    Seminal plasma metabolomics reveals lysine and serine dysregulation as unique features distinguishing between prostate cancer tumors of Gleason grades 6 and 7.
    Prostate. 2021 Jun 7. doi: 10.1002/pros.24145.
    PubMed     Abstract available


  234. WANG L, Li H, Li Z, Li M, et al
    Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Prostate. 2021;81:508-520.
    PubMed     Abstract available


  235. NIZIALEK E, Lim SJ, Wang H, Isaacsson Velho P, et al
    Genomic profiles and clinical outcomes in primary versus secondary metastatic hormone-sensitive prostate cancer.
    Prostate. 2021;81:572-579.
    PubMed     Abstract available


  236. WESTHOFEN T, Buchner A, Schlenker B, Becker A, et al
    A matter of size? Health-related quality of life after radical prostatectomy for patients with giant prostates.
    Prostate. 2021;81:443-451.
    PubMed     Abstract available


  237. CIPOLLARI S, Jamshidi N, Du L, Sung K, et al
    Tissue clearing techniques for three-dimensional optical imaging of intact human prostate and correlations with multi-parametric MRI.
    Prostate. 2021;81:521-529.
    PubMed     Abstract available


  238. XIAO GQ, Ho G, Suen C, Hurth KM, et al
    Comparative study of neuroendocrine acquisition and biomarker expression between neuroendocrine and usual prostatic carcinoma.
    Prostate. 2021;81:469-477.
    PubMed     Abstract available


    May 2021
  239. LOEB S, Li R, Sanchez Nolasco T, Byrne N, et al
    Barriers and facilitators of germline genetic evaluation for prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24172.
    PubMed     Abstract available


  240. QUHAL F, Rajwa P, Mori K, Laukhtina E, et al
    The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer.
    Prostate. 2021 May 31. doi: 10.1002/pros.24173.
    PubMed     Abstract available


  241. SI S, Zheng B, Wang Z, Niu Z, et al
    Does surgery benefit patients with oligometastatic or metastatic prostate cancer? - A retrospective cohort study and meta-analysis.
    Prostate. 2021 May 31. doi: 10.1002/pros.24170.
    PubMed     Abstract available


  242. MISHRA A, Zennami K, Velarde E, Thorek DLJ, et al
    Longitudinal measurement of subcutaneous and intratibial human prostate cancer xenograft growth and response to ionizing radiation by plasma Alu and LINE-1 ctDNA: A comparison to standard methods.
    Prostate. 2021 May 25. doi: 10.1002/pros.24171.
    PubMed     Abstract available


  243. ZHU S, Chen J, Ni Y, Zhang H, et al
    Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients.
    Prostate. 2021 May 24. doi: 10.1002/pros.24167.
    PubMed     Abstract available


  244. WENZEL M, Wurnschimmel C, Chierigo F, Tian Z, et al
    Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy.
    Prostate. 2021 May 19. doi: 10.1002/pros.24169.
    PubMed     Abstract available


  245. FERRARIS F, Yaber F, Smith AB, Barreiro D, et al
    The end of "very low risk" in localized prostate cancer?
    Prostate. 2021 May 19. doi: 10.1002/pros.24168.
    PubMed    


  246. SARTOR O, Appukkuttan S, Weiss J, Tsao CK, et al
    Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
    Prostate. 2021 May 12. doi: 10.1002/pros.24143.
    PubMed     Abstract available


  247. XU J, Isaacs WB, Mamawala M, Shi Z, et al
    Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
    Prostate. 2021 May 6. doi: 10.1002/pros.24140.
    PubMed     Abstract available


  248. BANERJEE M, Li Z, Gao Y, Lai F, et al
    Inverse agonism at the Na/K-ATPase receptor reverses EMT in prostate cancer cells.
    Prostate. 2021 May 6. doi: 10.1002/pros.24144.
    PubMed     Abstract available


  249. WANG V, Geybels MS, Jordahl KM, Gerke T, et al
    A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
    Prostate. 2021 May 6. doi: 10.1002/pros.24148.
    PubMed     Abstract available


  250. DE GROOT AE, Myers KV, Krueger TEG, Kiemen AL, et al
    Characterization of tumor-associated macrophages in prostate cancer transgenic mouse models.
    Prostate. 2021 May 5. doi: 10.1002/pros.24139.
    PubMed     Abstract available


  251. CHI JT, Lin PH, Tolstikov V, Oyekunle T, et al
    The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
    Prostate. 2021 May 5. doi: 10.1002/pros.24136.
    PubMed     Abstract available


  252. ONAL C, Ozyigit G, Oymak E, Guler OC, et al
    Clinical parameters and nomograms for predicting lymph node metastasis detected with (68) Ga-PSMA-PET/CT in prostate cancer patients candidate to definitive radiotherapy.
    Prostate. 2021 May 5. doi: 10.1002/pros.24142.
    PubMed     Abstract available


  253. WENZEL M, Wurnschimmel C, Nocera L, Colla Ruvolo C, et al
    The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients.
    Prostate. 2021;81:339-346.
    PubMed     Abstract available


  254. LEON P, Cancel-Tassin G, Bourdon V, Buecher B, et al
    Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.
    Prostate. 2021;81:318-325.
    PubMed     Abstract available


  255. ZHAO H, Howard LE, De Hoedt AM, Terris MK, et al
    Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
    Prostate. 2021;81:390-397.
    PubMed     Abstract available


    April 2021
  256. TAN B, Chen X, Fan Y, Yang Y, et al
    STAT3 phosphorylation is required for the HepaCAM-mediated inhibition of castration-resistant prostate cancer cell viability and metastasis.
    Prostate. 2021 Apr 28. doi: 10.1002/pros.24141.
    PubMed     Abstract available


  257. BALLAL S, Yadav MP, Sahoo RK, Tripathi M, et al
    (225) Ac-PSMA-617-targeted alpha therapy for the treatment of metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24137.
    PubMed     Abstract available


  258. QU F, Gu Y, Xue M, He M, et al
    Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24134.
    PubMed     Abstract available


  259. HISHIDA S, Kawakami K, Fujita Y, Kato T, et al
    Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24138.
    PubMed     Abstract available


  260. BOSLAND MC, Nettey OS, Phillips AA, Anunobi CC, et al
    Prevalence of prostate cancer at autopsy in Nigeria-A preliminary report.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24133.
    PubMed     Abstract available


  261. ONAL C, Kose F, Ozyigit G, Aksoy S, et al
    Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    Prostate. 2021 Apr 27. doi: 10.1002/pros.24132.
    PubMed     Abstract available


  262. BAZZI LA, Sigurdardottir LG, Sigurdsson S, Valdimarsdottir U, et al
    Exploratory assessment of pineal gland volume, composition, and urinary 6-sulfatoxymelatonin levels on prostate cancer risk.
    Prostate. 2021 Apr 16. doi: 10.1002/pros.24130.
    PubMed     Abstract available


  263. THULIN MH, Maatta J, Linder A, Sterbova S, et al
    Inhibition of STAT3 prevents bone metastatic progression of prostate cancer in vivo.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24125.
    PubMed     Abstract available


  264. WANG Y, Wu G, Fan L, Pan J, et al
    The prognostic nomogram including MRI for locally advanced prostate cancer treated by radical prostatectomy.
    Prostate. 2021 Apr 6. doi: 10.1002/pros.24126.
    PubMed     Abstract available


    March 2021
  265. SWANSON GP, Lenz L, Stone S, Cohen T, et al
    Cell-cycle risk score more accurately determines the risk for metastases and death in prostatectomy patients compared with clinical features alone.
    Prostate. 2021;81:261-267.
    PubMed     Abstract available


  266. TAN YG, Khalid F, Huang HH, Chen K, et al
    Prostatic ductal adenocarcinoma variant predicts worse pathological and oncological outcomes: Insight from over 1000 consecutive patients from a large prospective uro-oncology registry.
    Prostate. 2021;81:242-251.
    PubMed     Abstract available


  267. LI Y, Ge C, Franceschi RT
    Role of Runx2 in prostate development and stem cell function.
    Prostate. 2021;81:231-241.
    PubMed     Abstract available


    February 2021
  268. LEE JM, Kim U, Yang H, Ryu B, et al
    TALEN-mediated generation of Nkx3.1 knockout rat model.
    Prostate. 2021;81:182-193.
    PubMed     Abstract available


    January 2021
  269. ZHU Y, Wen J, Huang G, Mittlesteadt J, et al
    CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
    Prostate. 2021;81:81-88.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: